Show simple item record

dc.contributor.authorSonga, Patricia Mwebaze
dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorMugasha, Estella Birabwa
dc.contributor.authorOcama, Ponsiano
dc.contributor.authorKambugu, Andrew
dc.date.accessioned2012-05-25T14:21:23Z
dc.date.available2012-05-25T14:21:23Z
dc.date.issued2007
dc.identifier.citationSonga, P.M., Castelnuovo, B., Mugasha, E.B., Ocama, P., Kambugu, A. (2007). Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a Resource-Limited Setting (Uganda). Clinical Infectious Diseases, 45en_US
dc.identifier.issn1058-4838
dc.identifier.urihttp://hdl.handle.net/123456789/1806
dc.identifier.uriDOI: 10.1086/520023
dc.identifier.urihttp://hdl.handle.net/10570/586
dc.description.abstractWe describe 24 Ugandan patients with human immunodeficiency virus infection who developed symptomatic hyperlactatemia associated with the use of nucleoside analogues. All patients were receiving combination therapy that contained stavudine. The median serum lactate level was 6.6 mmol/L. All patients had their antiretroviral treatment regimen discontinued. Hospital admission was required for 5 patients. Five patients died.en_US
dc.language.isoenen_US
dc.publisherUniversity of Chicago Pressen_US
dc.subjectHyperlactatemiaen_US
dc.subjectResource-Limited Settingen_US
dc.subjectHIV/AIDSen_US
dc.subjectUgandaen_US
dc.subjectHyperlactatemiaen_US
dc.subjectAntiretroviral therapyen_US
dc.titleSymptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a Resource-Limited Setting (Uganda).en_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record